- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07527741
Une étude visant à évaluer les schémas thérapeutiques et l'observance du traitement chez les participantes atteintes d'un cancer du sein précoce HER2-positif après la décentralisation du traitement (Close2HER)
Recherche en Vie Réelle des Modèles de Traitement et de l'Adhérence au Traitement dans le Cancer du Sein Précoce HER2-positif en Serbie Après la Décentralisation du Traitement (Close2HER)
The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).
This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Sauvegarde des contacts de l'étude
- Nom: Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
- Numéro de téléphone: 888-662-6728 (U.S. Only)
- E-mail: global-roche-genentech-trials@gene.com
Lieux d'étude
-
-
Bolnička 65
-
Loznica, Bolnička 65, Serbie, 15300
- Recrutement
- Health Centre Loznica
-
-
Bratstva Jedinstva 135
-
Požarevac, Bratstva Jedinstva 135, Serbie, 12000
- Recrutement
- General Hospital Požarevac
-
-
Dragiše Mišovića 1
-
Bor, Dragiše Mišovića 1, Serbie, 19210
- Recrutement
- Healthcare Centre Bor
-
-
Dunavska 1-3
-
Kladovo, Dunavska 1-3, Serbie, 19320
- Recrutement
- Health Centre Kladovo
-
-
Knez Mihailova 51
-
Smederevo, Knez Mihailova 51, Serbie, 11300
- Recrutement
- Health Centre ''Sveti Luka'' Smederevo
-
-
Miloša Trebinjca 11
-
Pančevo, Miloša Trebinjca 11, Serbie, 26000
- Recrutement
- General Hospital Pančevo
-
-
Pasterova 14
-
Belgrade, Pasterova 14, Serbie, 11000
- Recrutement
- Institute for Onocology and Radiology of Serbia
-
-
Popa Karana 2-4
-
Šabac, Popa Karana 2-4, Serbie, 15000
- Recrutement
- General Hospital "Dr Laza K. Lazarevic" Sabac
-
-
Sinđelićeva 62
-
Valjevo, Sinđelićeva 62, Serbie, 14000
- Recrutement
- Health Centre Valjevo
-
-
Vuka Karadžića 147
-
Smederevska Palanka, Vuka Karadžića 147, Serbie, 11420
- Recrutement
- General Hospital ''Stefan Visoki'' Smederevska Palanka
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population will consist of participants diagnosed with HER2-positive eBC who are initiating or undergoing treatment following a nationwide healthcare policy change in Serbia that decentralized the administration of anti-HER2 therapies.
La description
Inclusion Criteria:
- Diagnosis of stage II and III HER2+ eBC according to European Society For Medical Oncology (ESMO) guidelines
- Underwent curative-intent surgical resection for BC
- Histologically documented HER2-positive BC (determined per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines) before or after surgery
Exclusion Criteria:
- Any medical or psychiatric condition that, in the investigator's opinion, would compromise the participant's ability to provide informed consent or to complete study-related questionnaires
- Receipt of prior neoadjuvant or adjuvant therapy for HER2+ BC at a center other than the 10 participating study sites (Bor, Kladovo, Institute for oncology and Radiology of Serbia (IORS), Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, Valjevo)
- Participants administratively belonging to the following secondary centers: Bor, Kladovo, Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, or Valjevo, who initiated neoadjuvant therapy at IORS instead of their local secondary center
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Group 1: Cohort A
Participants who received neoadjuvant therapy and achieved pathological complete response (pCR) and receive their adjuvant treatment at a designated secondary or tertiary center, administratively assigned based on their place of residence will be observed to assess the impact on quality of life (QoL) and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 2: Cohort B
Participants who received neoadjuvant therapy at a secondary center and were subsequently found to have residual invasive disease will be referred to a centralized referent tertiary institution to receive their adjuvant treatment and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort C
Participants who received neoadjuvant therapy at their designated tertiary center, which is the institution administratively assigned based on their place of residence, and subsequently found to have residual invasive disease will continue with adjuvant treatment at the same institution, and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
|
Group 1: Cohort D
Participants who missed neoadjuvant therapy and underwent primary BC surgery will start adjuvant treatment at their designated secondary hospital or tertiary center, which is the institution administratively assigned based on their place of residence and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Taux d'Adhérence au Traitement
Délai: Jusqu'à 2,25 ans
|
Jusqu'à 2,25 ans
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Taux d'achèvement du traitement anti-HER2
Délai: Jusqu'à 2,25 ans
|
Jusqu'à 2,25 ans
|
|
|
Pourcentage de participants avec ≥1 retard de dose dépassant un seuil prédéfini (3 semaines) par rapport à la date prévue
Délai: Jusqu'à 2,25 ans
|
Jusqu'à 2,25 ans
|
|
|
Délai d'initiation du traitement adjuvant
Délai: Temps entre la chirurgie et le début du traitement adjuvant (jusqu'à environ 1,25 ans)
|
Temps entre la chirurgie et le début du traitement adjuvant (jusqu'à environ 1,25 ans)
|
|
|
Mean Travel Burden Between Group 1 (Cohorts A, C, D) and Group 2 (Cohort B) During the Adjuvant Therapy Phase
Délai: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective components. Objective travel burden is defined by the one-way travel distance (in kilometers [km]) and one-way travel time (in minutes) from the participant's residence to the treatment center. Subjective travel burden will capture the participant's personal experience and will be assessed using patient-reported outcomes collected via dedicated questionnaires. |
Up to 2.25 years
|
|
Cohort B: Change in Intra-participant Travel Burden Between the Neoadjuvant and Adjuvant Treatment Centers
Délai: Up to 2.25 years
|
Travel Burden is a composite measure encompassing both objective and subjective metrices. Objective travel metrics include driving distance and travel time and subjective, patient-reported metrics include out-of-pocket costs, mode of transport, and perceived travel-related challenges. Intra-participant travel burden between the Neoadjuvant and Adjuvant treatment centers will be done as a longitudinal analysis of the change in these metrics from the neoadjuvant to the adjuvant phase. |
Up to 2.25 years
|
|
Difference in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score, Between Participants of Cohort B and Cohort C
Délai: At 6 months post-baseline
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better health-related quality of life (HRQoL). |
At 6 months post-baseline
|
|
Mean Intra-patient Change in the EORTC QLQ-C30 GHS/QoL Score
Délai: Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, & social), 3 symptom scales (fatigue, nausea & vomiting, & pain), GHS/QoL & 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better HRQoL. |
Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12
|
|
Time to Neoadjuvant Treatment Initiation
Délai: At Baseline
|
Time to Neoadjuvant Treatment Initiation was defined as time from early breast cancer (eBC) diagnosis to the start of neoadjuvant treatment. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Time to Surgery
Délai: At Baseline
|
Time to surgery was defined as the time from the neoadjuvant treatment completion to surgery. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Treated at Least Once With Neoadjuvant Therapy
Délai: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants Not Treated With Neoadjuvant Therapy
Délai: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
|
Percentage of Participants With pCR After Neoadjuvant Systemic Therapy Completion
Délai: At Baseline
|
Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records. |
At Baseline
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trials, Hoffmann-La Roche
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- ML46477
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .